RxSight (RXST) CMO Dr. Ronald Kurtz Sells 5,100 Shares

What Happened Dr. Ronald M. Kurtz, Chief Medical Officer of RxSight (RXST), had 13,425 restricted stock units (RSUs) convert/exercise on August 31, 2026 (each RSU = one share). A block of 13,425 shares was recorded as disposed in connection with that conversion (see tax withholding note). On September 2, 2026 he sold 5,100 shares in an open-market transaction at $6.96 per share, generating $35,496 total. These transactions are primarily a vesting/conversion of RSUs with a subsequent small open-market sale.

Key Details

• Transaction dates: RSU conversion/exercise recorded 2026-08-31; open-market sale on 2026-09-02.
• Sale price/value: 5,100 shares sold at $6.96 = $35,496.
• Derivative activity: 13,425 shares reported as acquired via conversion/exercise (code M) on 2026-08-31 and 13,425 shares reported disposed (code M) at $0 in the same period — tied to RSU vesting.
• Footnotes: F1 defines each RSU = one share; F2 states shares were sold/used to cover tax withholding for RSU vesting (not a discretionary sale); F4 shows the RSU vests 1/6th on Aug 31, 2026 (with further scheduled vesting through Feb 28, 2029).
• Ownership note: F3 indicates certain shares are held by Cricklewood LP, for which the reporting person is a manager and shares voting/investment control with his spouse.
• Filing: Form filed 2026-09-02 reporting the Aug 31 transactions (filing date shown on report).

Context The filings show vesting/conversion of RSUs (derivative exercise) and routine share disposals to satisfy tax withholding plus a small open-market sale. The 13,425-share conversion represents one scheduled tranche (1/6th) of the underlying RSU award; the separate 5,100-share sale raised ~$35k. These types of transactions commonly reflect compensation vesting and tax obligations rather than an independent signal of insider sentiment.